New bacterial vaginosis drug passes first safety check in healthy volunteers
NCT ID NCT07302035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called GenSci142 in 30 healthy Chinese women to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo, and are monitored for side effects for 15 days. The goal is to gather safety information before testing the drug in people with bacterial vaginosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL VAGINOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vaginal device aims to boost infection treatment
- Blue light could soothe vaginal disorders without hormones
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- Can a probiotic stop bacterial vaginosis recurrence?
- Quick vaginal infection test could beat standard diagnosis
- Natural prebiotic could beat antibiotics for thrush and BV